CNH and DENSO Recognized for Outstanding Brand Protection Efforts at EMEA SEC 2025
CNH and DENSO were respectively awarded for their contributions—one as the Anti-Counterfeit Technology Leader and the other as a Counterfeit Awareness Advocate. While CNH was recognized for its strategic use of digital authentication to ensure product authenticity and protect customer trust, DENSO was honored for spearheading awareness initiatives that educate customers and industry stakeholders about the risks associated with counterfeit automotive parts.
" At EMEA SEC 2025, we believe that meaningful progress in the fight against counterfeiting stems from strong collaboration. CNH and DENSO exemplify how partnerships—like those with Ennoventure—can transform ideas into impactful brand protection strategies across global markets, " said Hazem Ibrahim , Founder & CEO, ASIAS Security Group SDN BHD.
"We are thrilled to see our customers, CNH and DENSO, receive these prestigious awards at EMEA SEC 2025," said Padmakumar Nair, CEO at Ennoventure, Inc."Their recognition is a testament to the impact of our AI-powered cryptographic solutions in securing brands and protecting consumers. This win reinforces our commitment to providing technology that drives meaningful change in brand protection."
About Ennoventure, Inc.
Ennoventure, Inc. is a global SaaS company leading the digital revolution in brand protection, distinguished by its patented invisible signature powered by AI and cryptography. With innovation and people at our core, we empower brands and consumers by authenticating product packages and transforming them into intelligent, connected packaging. Our solutions seamlessly integrate into product packaging without process changes or capital investment. Trusted by major brands worldwide, billions of product packages carry our invisible signatures across industries, including automotive and industrial spare parts, FMCG, agrochemicals, and more. Ennoventure, Inc. is headquartered in Massachusetts and has offices in Dubai and India .
Visit www.ennoventure.com to redefine your brand protection strategy.
Media Contact
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors SAN DIEGO and CALGARY, AB, July 16, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers. The translational research included the analysis of blood and tumor samples from patients in the GOBLET (pancreatic ductal adenocarcinoma (PDAC) and other gastrointestinal cancers) and AWARE-1 (breast cancer) studies. Analyses revealed consistent immune activation signatures, including: Upregulation of interferons, CXCL9/10/11, and PD-L1 Conversion of immunologically 'cold' tumors into 'hot' phenotypes Expansion and mobilization of tumor-infiltrating lymphocyte (TIL) clones in the blood, which correlates with a reduction in tumor size Modulation of the tumor microenvironment (TME) to enhance responsiveness to immune therapies "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, Chief Executive Officer of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." The GOBLET study continues to enroll PDAC and anal carcinoma patients, and additional translational data readouts are expected next year. The Company expects these and its other clinical data to support its focused and aggressive regulatory path and serve as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors. As regulatory conversations progress throughout the summer, the Company expects to provide an updated clinical timeline before the end of the third quarter. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our expectation that our data supports our focused and aggressive regulatory path and serves as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected]
Globe and Mail
2 hours ago
- Globe and Mail
AIG Appoints John Neal as President
American International Group, Inc. (NYSE: AIG) today announced that John Neal will be joining AIG as President, effective December 1, 2025 . In this role, Mr. Neal will report to Chairman & CEO, Peter Zaffino and lead AIG's General Insurance organization, which includes the North America Commercial Insurance, International Commercial Insurance and Global Personal Insurance businesses. He will become a member of AIG's Executive Leadership team. This press release features multimedia. View the full release here: Mr. Zaffino said, 'I have known John for more than 20 years, and he is widely recognized as one of the most accomplished insurance executives in the industry. His appointment adds significant depth, global underwriting experience, and talent to our leadership team. I am confident that John will continue to enhance our culture of underwriting excellence. I look forward to working with him as we continue to drive profitable, sustainable growth and further strengthen our relationships with our valued clients and partners across the industry.' 'AIG is an iconic, global insurance industry leader, recognized for the deep technical expertise of its team and its remarkable strategic repositioning,' said Mr. Neal. 'I am honored to take on the role of President and look forward to working closely with Peter and AIG's talented colleagues around the world on behalf of our clients and stakeholders.' Mr. Neal was formerly the CEO of Lloyd's of London, a leading insurance marketplace, serving in the role from October 2018 to January 2025. He is credited with leading its successful turnaround during that time. Before Lloyd's, Mr. Neal was the Group CEO of QBE, where he held several senior leadership roles throughout his career, including Chief Underwriting Officer and Chief Operations Officer for the company's European operations. About AIG American International Group, Inc. (NYSE: AIG) is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals in more than 200 countries and jurisdictions protect their assets and manage risks through AIG operations, licenses and authorizations as well as network partners. For additional information, visit This website with additional information about AIG has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release. AIG is the marketing name for the worldwide operations of American International Group, Inc. All products and services are written or provided by subsidiaries or affiliates of American International Group, Inc. Products or services may not be available in all countries and jurisdictions, and coverage is subject to underwriting requirements and actual policy language. Non-insurance products and services may be provided by independent third parties. Certain property casualty coverages may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds, and insureds are therefore not protected by such funds.
Globe and Mail
2 hours ago
- Globe and Mail
Monro, Inc. to Report First Quarter Fiscal 2026 Earnings on July 30, 2025
Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, will release its first quarter fiscal 2026 earnings on July 30, 2025. The Company will host a conference call and audio webcast on Wednesday, July 30, 2025 at 8:30 a.m. Eastern Time. The conference call may be accessed by dialing 1-833-470-1428 and using the required access code of 932091. A replay will be available approximately two hours after the recording through Wednesday, August 13, 2025 and can be accessed by dialing 1-866-813-9403 and using the required access code of 386938. A replay can also be accessed via audio webcast at the Investors section of the Company's website, located at About Monro, Inc. Monro, Inc. (NASDAQ: MNRO) is one of the nation's leading automotive service and tire providers, delivering best-in-class auto care to communities across the country, from oil changes, tires and parts installation, to the most complex vehicle repairs. With a focus on sustainable growth, the Company generated approximately $1.2 billion in sales in fiscal 2025. Monro brings customers the professionalism and high-quality service they expect from a national retailer, with the convenience and trust of a neighborhood garage. Monro's highly trained teammates and certified technicians bring together hands-on experience and state-of-the-art technology to diagnose and address automotive needs every day to get customers back on the road safely. For more information, please visit
